Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 27, 2025; 17(6): 104073
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.104073
Effect of rapamycin nanoparticles in an animal model of primary biliary cholangitis
Yu-Shu Yang, Xian-Rui Li, Zhi-Min Wang, Lin Zheng, Jin-Long Li, Xiao-Lin Cui, Yan-Biao Song, Jun-Ji Ma, Hui-Fang Guo, Li-Xia Gao, Xiao-Hui Zhou
Yu-Shu Yang, Zhi-Min Wang, Jin-Long Li, Xiao-Lin Cui, Hui-Fang Guo, Li-Xia Gao, Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Xian-Rui Li, College of Pharmacy, Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Zhi-Min Wang, Department of Rheumatology and Immunology, The Affiliated Hospital of Hebei University, Baoding 071000, Hebei Province, China
Lin Zheng, Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Yan-Biao Song, Central Laboratory, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Jun-Ji Ma, Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Shijiazhuang 050000, Hebei Province, China
Xiao-Hui Zhou, School of Food and Biology, Hebei University of Science and Technology, Shijiazhuang 050000, Hebei Province, China
Co-first authors: Yu-Shu Yang and Xian-Rui Li.
Co-corresponding authors: Li-Xia Gao and Xiao-Hui Zhou.
Author contributions: Yang YS and Li XR contributed equally to this work, contributed to methodology, formal analysis, data extraction, preparation of rapamycin nanoparticles and editing; Wang ZM contributed to data extraction, data curation; Zheng L, Li JL and Cui XL contributed to animal rearing, specimen collection and treatment; Song YB and Ma JJ were involved in guidance of pathological methods; Guo HF was involved in methodology and supervision; Gao LX contributed to conceptualization, funding acquisition, methodology and editing; Zhou XH contributed to nanoparticle design and experimental idea design; all authors have read and approved the final version to be published.
Supported by Cultivation Project of Hebei Natural Science Foundation-Precision Medicine Joint Fund, No. H2021206239.
Institutional animal care and use committee statement: All mice were housed in the specific pathogen-free-grade breeding room of the Experimental Animal Center of The Second Hospital of Hebei Medical University (22 °C, 55% humidity, and 12-hours day-night cycle) and were raised in strict accordance with the animal ethics requirements of the Experimental Animal Center of The Second Hospital of Hebei Medical University.
Conflict-of-interest statement: All the authors declare no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: All the authors share the data.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Xia Gao, MD, PhD, Chief Physician, Professor, Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang 050000, Hebei Province, China. 27100287@ hebmu.edu.cn
Received: December 16, 2024
Revised: February 24, 2025
Accepted: May 21, 2025
Published online: June 27, 2025
Processing time: 192 Days and 3.9 Hours
Core Tip

Core Tip: Primary biliary cholangitis (PBC) is a chronic autoimmune-mediated cholestatic liver disease, which can gradually progress to liver fibrosis, cirrhosis. The global incidence of PBC has been increasing year by year in recent decades. But there are few effective drugs, the effect of nanoparticles encapsulating rapamycin on the treatment of PBC using an animal model is examined in this paper, targeting at new approaches for the treatment of PBC.